新早期胃癌标志物PRDX4通过清除ROS促进胃癌的发生发展（英文）

胃癌是全球第四大最常见的癌症,也是全球癌症中引起死亡的第二大原因。为了降低胃癌的死亡率,目前亟需解决的问题是发现新的早期胃癌特异性的标志物,提高早期胃癌的检出率,从而从根本上解决胃癌死亡率高的问题。实验室前期研究发现过氧化物酶4 (Peroxiredoxin 4,PRDX4)具有早期胃癌标志物的潜能,文中通过建立恶性转化模型及转化细胞过表达等方法,研究PRDX4在转化细胞中的作用。结果显示PRDX4通过减少转化细胞中活性氧(Reactive oxygen species,ROS)含量,使细胞处在利于生长增殖的微环境中,从而促进细胞发生恶性转化,即PRDX4通过清除ROS促进胃癌的发生发展。     

早期胃癌血清特异标志物过氧化物酶4核酸适配体的筛选、鉴定与应用

胃癌是世界上死亡率第三的重大疾病,而在早期阶段却有着良好的治愈率和生存率。因此,找到针对早期胃癌的特异性标志物从而提高早期胃癌的检出率,是目前亟待解决的问题。在本实验室的早期研究中,发现过氧化物酶4（peroxiredoxin-4,PRDX4）有极大的潜能作为早期胃癌的特异性标志物,并且由于蛋白质结构的特殊性,能够分泌至血清中,为早期胃癌的无创化诊断提供了可能。本文为寻找血清中PRDX4蛋白的特异性适配体,通过消减-SELEX方法找到9种适配体。经特异性和亲和力分析后,证实其中Ap-EGACS-11在9种适配体中具有最高的特异性和亲和力。随后在适配体的验证研究中证实,相对于进展期胃癌病人血清、结直肠癌病人血清和正常人血清,Ap-EGACS-11对早期胃癌病人血清的检出率最高。该结果表明,PRDX4具有早期胃癌特异性血清标志物的潜能,且Ap-EGACS-11可直接作为早期胃癌的检测试剂。     

胃癌细胞中SMAD-4与TGF-β通过抑制RAS/ERK途径促进PTEN表达

SMAD-4在肿瘤抑制方面有重要作用,但它在肿瘤发生中的作用及其与细胞周期进程中的一种关键调控因子——PTEN(phosphatase and tensin homolog deleted on chromosome 10)的关系仍存在争议.分别在人胚肾细胞(293T)及人胃癌细胞(MGC-803)中研究SMAD-4及TGF-β信号通路对PTEN基因表达的影响.结果发现,在293T细胞中,SMAD-4与TGF-β促进PTEN表达,而MGC-803细胞中,SMAD-4与TGF-β抑制PTEN转录.进一步研究发现,胃癌细胞中,SMAD-4与转化生长因子β(TGF-β)对PTEN的抑制可被PD98059(MEK抑制剂)解除.此外,SMAD-4的核转移也明显促进PTEN表达,并且PD98059存在下,SMAD-4与TGF-β协同刺激可促进胃癌细胞凋亡.综上,实验发现,SMAD-4作为一种co-Smad蛋白,通过TGF-β信号途径影响PTEN表达.     

CD90过表达影响胃癌细胞AGS的干性特征

2019年中国癌症报告显示,胃癌发病率仅次于肺癌,位列第二,其死亡率排在所有肿瘤的第三位,严重危害人们健康.筛查和鉴定胃癌的早期检测标志物、寻找胃癌治疗的分子靶点,对于降低胃癌致死率至关重要. CD90 (THY1)是一种细胞表面糖蛋白,在肿瘤细胞增殖、转移以及血管生成中发挥重要作用. CD90异常表达与干细胞特性有关,促进肿瘤的起始与转移.但CD90与胃癌细胞干性特征之间的关系尚未见文献报道.本研究发现,CD90过表达增加胃癌细胞AGS的侧群细胞(SP细胞)比例,影响其膜表面ABCG2、CD105等干性标记物的蛋白质表达水平,同时也影响胃癌细胞AGS胞内NANOG、SOX2等干性标记物的m RNA表达水平,mRNA芯片和Western-blot技术揭示CD90过表达可能通过调控PI3K/Akt和JNK/ERK1/2信号通路活性,影响胃癌细胞AGS的干性特征.本实验结果为胃癌潜在分子靶点的鉴定提供了新的思路.     

microRNA-215异常激活抑制Dicer1促进肝癌细胞迁移和转化

microRNA异常表达促进癌症的发生发展.本研究通过microRNA表达谱分析2个肝癌细胞和2个正常细胞microRNA的表达,寻找与肝癌相关的microRNA,发现microRNA-215在肝癌细胞中高表达,q RT-PCR验证microRNA-215在肝癌细胞呈显著高表达.进一步研究发现,microRNA-215直接靶向Dicer1基因的3′UTR并抑制Dicer1蛋白表达,Dicer1是microRNA加工成熟过程中必需的蛋白.过表达microRNA-215抑制Dicer1从而促进肝癌细胞迁移和转化,而抑制microRNA-215表达起相反作用.Dicer1抑制后,许多抑癌microRNA表达被抑制,从而促进迁移和转化.相对于癌旁组织,Dicer1在肝癌组织呈明显低表达.本研究揭示,microRNA-215异常活化并抑制Dicer1表达与肝癌发展相关.     

未折叠蛋白质与感染、炎症和癌症

未折叠蛋白(Unfolded proteins,UP)是蛋白质质量控制的对象,其可诱发UP应答(UPR),介导细胞死亡或炎症反应。在多种感染、炎症和癌症疾病中,病原体或恶性转化细胞可劫持UPR,在避免细胞死亡的前提下,介导慢性炎症反应,从而起到促进疾病发生发展的作用。这种UP相关炎症与疾病进展之间的机制联系目前不清楚,且研究技术手段缺乏。本文对UP与感染、炎症和癌症的关系以及UP蛋白质组学研究技术的进展进行综述,核心目的是总结上述领域最新研究思路,并促进以UP为靶向的生物学和疾病推动的科学研究。     

二十二碳六烯酸促进无葡萄糖条件下乳腺癌细胞MDA-MB-231死亡

为了探究二十二碳六烯酸(docosahexaenoic acid,DHA)抗乳腺癌的机制,采用流式细胞术分析细胞死亡率,H2DCFDA探针流式细胞术测定细胞内活性氧(reactive oxygen species,ROS)水平,Western blotting方法检测细胞内剪切型Caspase-3的变化。结果发现在无葡萄糖条件下,DHA以浓度依赖性方式促进乳腺癌细胞MDA-MB-231死亡。在这个过程中,DHA促使细胞内ROS水平明显升高,然而,当DHA和抗氧化剂N-乙酰-半胱氨酸(N-acetyl-L-cystein,NAC)共处理细胞时,细胞死亡率和细胞内ROS水平均明显降低。Western blotting检测结果表明DHA可以引起Caspase-3的切割,同时,这种变化可以被NAC抑制。结果表明在无葡萄糖条件下,DHA可以通过增加细胞内ROS的水平,激活Caspase凋亡通路,进而促进乳腺癌细胞MDA-MB-231死亡。     

NADPH氧化酶与ROS信号区域化

最近有关活性氧物质 (ROS)的研究取得了突飞猛进的进展,尤其是其作为第二信使介导了许多生理性与病理性细胞事件,包括细胞分化、过度生长、增殖及凋亡.为了避免ROS的毒性产生特异性的信号转导,ROS的产生与代谢必须被严格调控;其具体的调控机制一直是人们关注的焦点. 最近有关ROS区域化观点的提出解决了这一问题. NADPH是生成ROS的主要来源. 研究发现,NADPH氧化酶及其衍生的ROS存在于机体的多种组织内,且在细胞中呈区域化分布,对细胞内信号的精确调控具有至关重要的作用. NADPH一方面通过小窝/脂筏组装成功能型复合物,从而产生ROS区域化;另一方面,NADPH通过其不同亚细胞定位亚基与各种靶蛋白之间的相互作用,产生ROS特异性. 本文系统综述了NADPH衍生的ROS信号区域化,为进一步理解ROS信号在各种生理或病理过程的分子调控机制提供理论依据.     

S100A4基因表达在肿瘤转移中的作用

肿瘤转移是细胞恶性的重要标志之一,有许多基因和因子都参与这一过程。对S100A4基因的研究发现,它可参与细胞周期调控、细胞增殖与分化、血管生成、细胞外基质重建等多种生命过程,调控细胞的生长和运动。在某些特定的肿瘤细胞内,它的表达含量的增加可促进肿瘤细胞发生转移,并与癌症的发生具有某些相关性,可能对人类癌症的发生具有预后作用。现就S100A4基因表达与肿瘤转移的关系进行初步的探讨,以期对癌症的临床诊断提供一些参考。     

MicroRNA对胃癌调控作用的研究进展

微小RNA(microRNA, miRNA)是一类源于真核生物自身基因组的非编码小RNA,参与了肿瘤发生的多个阶段,通过直接靶向抑制其下游靶mRNA的表达或利用其竞争性内源RNA(如lncRNA)间接调控靶基因的表达,在癌症进程中发挥促癌或抑癌作用。胃癌是一种常见的高发病率、高转移率、高侵袭率和高死亡率的恶性肿瘤,大量研究表明,胃癌细胞的恶性生物学行为、表观遗传学改变和化疗耐药性等均与miRNAs的异常表达密切相关。特别注意的是,外泌体源性miRNAs通过外泌体的包装及运载,在细胞之间或细胞与微环境之间传递,也是胃癌进展中必不可少的一环。本文重点概述了miRNAs通过不同信号通路及调控机制在胃癌恶性增殖、凋亡、侵袭、转移、DNA甲基化和化疗耐药等方面的作用,针对miRNAs作用机制的研究可能为胃癌的诊断与治疗提供新见解。     

Immunochemical and molecular-Genetic markers in diagnostics of gastric cancer

Intensive studies of molecular mechanisms responsible for tumor transformation results in identification of new proteins and their genes involved into tumor development. These proteins may be used as markers of tumor transformation of cells and the level of their expression may be evaluated by means of modern highly sensitive and technological methods of analysis. This review summarized literature data on currently used immunohistochemical and molecular genetic markers of gastric cancer. It highlights genetic and epigenetic changes detected in nucleic acids of tumor tissue cells in malignant and benign gastric diseases as well as in the level of DNA circulating in blood of patients with gastric cancer.     

Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway

Severe side effects and complications such as gastrointestinal and hematological toxicities because of current anticancer drugs are major problems in the clinical management of gastric cancer, which highlights the urgent need for novel effective and less toxic therapeutic approaches. Hispolon, an active polyphenol compound, is known to possess potent antineoplastic and antiviral properties. In this study, we investigated the efficacy of hispolon in human gastric cancer cells and explored the cell death mechanism. Hispolon induced ROS-mediated apoptosis in gastric cancer cells and was more toxic toward gastric cancer cells than toward normal gastric cells, suggesting greater susceptibility of the malignant cells. The mechanism of hispolon-induced apoptosis was that hispolon abrogated the glutathione antioxidant system and caused massive ROS accumulation in gastric cancer cells. Excessive ROS caused oxidative damage to the mitochondrial membranes and impaired the membrane integrity, leading to cytochrome c release, caspase activation, and apoptosis. Furthermore, hispolon potentiated the cytotoxicity of chemotherapeutic agents used in the clinical management of gastric cancer. These results suggest that hispolon could be useful for the treatment of gastric cancer either as a single agent or in combination with other anticancer agents.     

PRDX2 promotes the proliferation of colorectal cancer cells by increasing the ubiquitinated degradation of p53

Colorectal cancer is the most common gastrointestinal cancer and causes severe damage to human health. PRDX2 is a member of the peroxiredoxin family reported to have a high level of expression in colorectal cancer. However, the mechanisms by which PRDX2 promotes the proliferation of colorectal cancer are still unclear. Here, the results indicated that PRDX2 expression was upregulated in colorectal cancer and closely correlated with poor prognosis. Functionally, PRDX2 promoted the proliferation of colorectal cancer cells. Mechanistically, PRDX2 could bind RPL4, reducing the interaction between RPL4 and MDM2. These findings demonstrate that the oncogenic property of PRDX2 may be attributed to its regulation of the RPL4-MDM2-p53 pathway, leading to p53 ubiquitinated degradation.Subject terms: Colorectal cancer, Colorectal cancer     

KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male

Gastric cancer is one of the top causes of cancer-related death around the world, and poor prognosis of gastric cancer is due to the lack of early detection and effective treatment especially in male. Here, we first revealed the role of histone lysine-specific demethylase 5D (KDM5D) in gastric cancer in male. KDM5D was associated with the metastasis of gastric cancer because of its critical role in the epithelial-mesenchymal transition of gastric cancer cells. Downregulation of KDM5D in gastric cancer cells significantly increase the number of migrated or invaded cells due to the increasing expressions of mesenchymal markers. Downregulation of KDM5D also promotes tumor formation of gastric cancer cell in vivo. For mechanism, downregulation of KDM5D could inhibit the demethylation in the promoter of CUL4A, which lead to the increasing expression of ZEB1 and decreasing expressions of p21 and p53. Collectively, KDM5D performed its role in metastasis of gastric cancer through demethylation in the promoter of CUL4A, and it suggested us a novel target in gastric cancer treatment in male.     

MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity

MicroRNAs (miRNAs) are non-coding RNAs that regulate the expression of target mRNAs. Altered expression of specific miRNAs in human gastric cancer progression has been reported; however, the role of miR-650 in gastric cancer is poorly understood. In this study, we show that miR-650 is involved in lymphatic and distant metastasis in human gastric cancer, and we find that ectopic expression of miR-650 promotes tumorigenesis and proliferation of gastric cancer cells. A luciferase reporter assay demonstrates that Inhibitor of Growth 4 (ING4) is a direct target of miR-650. Collectively, our study demonstrates that over-expression of miR-650 in gastric cancer may promote proliferation and growth of cancer cells, at least partially through directly targeting ING4. These findings help clarify the molecular mechanisms involved in gastric carcinogenesis and indicate that miR-650 modulation may be a bona fide miRNA-based treatment of gastric cancer.     

FYN promotes gastric cancer metastasis by activating STAT3-mediated epithelial-mesenchymal transition

Gastric cancer is one of the most lethal cancers worldwide. FYN, a gene that is differentially expressed in gastric cancer, is considered a critical metastasis regulator in several solid tumors, but its role in gastric cancer is still unclear. This study aimed to evaluate the role of FYN and test whether FYN promotes migration and invasion of gastric cancer cells in vitro and in vivo via STAT3 signaling. FYN was overexpressed in gastric cancer and positively correlated with metastasis. FYN knockdown significantly decreased cancer cell migration and invasion, whereas FYN overexpression increased cancer migration and invasion. Genetic inhibition of FYN decreased the number of metastatic lung nodules in vivo. Several epithelial-mesenchymal transition markers were positively correlated with FYN expression, indicative of FYN involvement in this transition. Furthermore, gene set enrichment analysis of a Cancer Genome Atlas dataset revealed that the STAT3 signaling pathway was positively correlated with FYN expression. STAT3 inhibition reversed the FYN-mediated epithelial-mesenchymal transition and suppressed metastasis. In conclusion, FYN promotes gastric cancer metastasis possibly by activating STAT3-mediated epithelial mesenchymal transition and may be a novel therapeutic target for gastric cancer.     

Protein arginine methyltransferase 1 coordinates the epithelial-mesenchymal transition/proliferation dichotomy in gastric cancer cells

Protein arginine methyltransferase 1 (PRMT1) is up-regulated and promotes migration, invasion and proliferation in wide range of cancers. However, we for the first time identify that PRMT1 promotes migration and invasion and inhibits proliferation in gastric cancer cells, a phenomenon called “migration-proliferation dichotomy”. First, we find that PRMT1 overexpression promotes migration and invasion and inhibits proliferation, whereas PRMT1 knockdown reverses the above abilities. Next, PRMT1 reduces the expression of epithelial marker E-cadherin and increases the expression of mesenchymal markers including N-cadherin, Vimentin, snail and β-catenin in gastric cancer cells. Furthermore, our studies show that PRMT1 silencing promotes the phosphorylation of LATS1, and then induces YAP phosphorylation, while overexpression of PRMT1 down-regulates the phosphorylation of LATS1 and YAP, indicating that PRMT1 inhibits EMT probably via Hippo signaling. Collectively, the present study reveals important roles of PRMT1 in progression of gastric cancer. Given the dual functions of PRMT1, it is as a potential drug target of gastric cancer with extreme caution.